Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome–positive acute …

S Giebel, A Czyz, O Ottmann, F Baron, E Brissot… - Cancer, 2016 - Wiley Online Library
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a standard of care for
patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL) …

[HTML][HTML] A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia

R Bassan, M Brüggemann, HS Radcliffe… - …, 2019 - ncbi.nlm.nih.gov
Abstract Minimal (or 'measurable') residual disease in acute lymphoblastic leukemia
appears to be a prognostic indicator, with potential value in informing individualized …

Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

NJ Short, E Jabbour, K Sasaki, K Patel… - Blood, The Journal …, 2016 - ashpublications.org
The impact of achieving complete molecular response (CMR) in Philadelphia chromosome-
positive (Ph+) acute lymphoblastic leukemia (ALL) remains undefined. We evaluated the …

The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis

A Ghobadi, M Slade, H Kantarjian… - Blood, The Journal …, 2022 - ashpublications.org
Abstract Historically, Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
(ALL) has been associated with poor outcomes, and allogeneic hematopoietic cell …

Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia …

K Sasaki, EJ Jabbour, F Ravandi, NJ Short… - Cancer, 2016 - Wiley Online Library
BACKGROUND The clinical efficacy of hyperfractionated cyclophosphamide, vincristine,
doxorubicin, and dexamethasone (HCVAD) plus ponatinib has not been compared with that …

Minimal residual disease in acute lymphoblastic leukemia

D Campana - Hematology 2010, the American Society of …, 2010 - ashpublications.org
In patients with acute lymphoblastic leukemia (ALL), treatment response is increasingly
evaluated with minimal residual disease (MRD) assays. ALL cells can be recognized by …

[HTML][HTML] Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome …

E Brissot, M Labopin, MM Beckers, G Socié… - …, 2015 - ncbi.nlm.nih.gov
This study aimed to determine the impact of tyrosine kinase inhibitors given pre-and post-
allogeneic stem cell transplantation on long-term outcome of patients allografted for …

Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic …

JM Ribera, A Oriol, M González, B Vidriales… - …, 2009 - pmc.ncbi.nlm.nih.gov
Background Imatinib, given concurrently or alternating with chemotherapy, has improved the
response and survival of patients with Philadelphia chromosome-positive acute …

Has MRD monitoring superseded other prognostic factors in adult ALL?

M Brüggemann, T Raff, M Kneba - Blood, The Journal of the …, 2012 - ashpublications.org
Significant improvements have been made in the treatment of acute lymphoblastic leukemia
(ALL) during the past 2 decades, and measurement of submicroscopic (minimal) levels of …

Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase …

V Bachanova, DI Marks, MJ Zhang, H Wang, M de Lima… - Leukemia, 2014 - nature.com
The efficacy of reduced intensity conditioning (RIC) allogeneic hematopoietic cell
transplantation (HCT) for Philadelphia chromosome positive (Ph+) acute lymphoblastic …